NCT01396707已完成2 期
A Phase II Study of Trastuzumab in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 55
- 试验地点
- 1
- 主要终点
- Overall response rate
研究概览
简要总结
This is an open-label, multicentre, prospective phase II trial designed to evaluate the efficacy and safety of trastuzumab in combination with capecitabine and oxaliplatin as first-line therapy in patients with recurrent and/or metastatic HER2 positive adenocarcinoma of the stomach or gastro-oesophageal junction.
详细描述
Patients will be administered 6 cycles of combination chemotherapy, unless withdrawn earlier due to unacceptable toxicity, disease progression, or consent withdrawal. Patients will continue to be treated with trastuzumab alone until disease progression, unacceptable toxicity or consent withdrawal after finishing a maximum 6 cycles of combination chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed adenocarcinoma of the stomach or gastro-oesophageal junction with inoperable locally advanced or recurrent and/or metastatic disease, not amenable to curative therapy.
- •Measurable disease, according to the Response Evaluation Criteria in Solid Tumors (RECIST), assessed using imaging techniques (CT or MRI).
- •HER2 positive tumour (primary tumour or metastasis) defined as either IHC2+ and FISH+ or IHC3+ according to the gastric cancer scoring system for HER2
- •ECOG Performance status 0, 1 or 2
- •Life expectancy of at least 3 months.
- •Male or female. Age over 20 year.
- •Signed informed consent.
排除标准
- •Previous chemotherapy for advanced/metastatic disease (prior adjuvant/neoadjuvant therapy is allowed if at least 6 months has elapsed between completion of adjuvant/neoadjuvant therapy and enrolment into the study; adjuvant/neoadjuvant therapy with platinum is not allowed).
- •Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome (e.g. patients with partial or total gastrectomy can enter the study, but not those with a jejunostomy tube).
- •Patients with active (significant or uncontrolled) gastrointestinal bleeding.
- •Residual relevant toxicity resulting from previous therapy (with the exception of alopecia), e.g. neurological toxicity over grade 2 NCI-CTCAE.
- •Other malignancy within the last 5 years, except for carcinoma in situ of the cervix, or basal cell carcinoma.
- •Neutrophil count < 1.5 × 109/L, or platelet count < 100 × 109/L.
- •Serum bilirubin > 1.5 × upper limit of normal (ULN); or, AST or ALT > 2.5 × ULN (or > 5 × ULN in patients with liver metastases); or, alkaline phosphatase > 2.5 × ULN (or > 5 × ULN in patients with liver metastases, or > 10 × ULN in patients with bone but no liver metastases); or, albumin < 25 g/L.
- •Creatinine clearance < 60 mL/min. Other Study Drug-Related Exclusion Criteria
- •History of documented congestive heart failure; angina pectoris requiring medication; evidence of transmural myocardial infarction on ECG; poorly controlled hypertension (systolic BP > 180 mmHg or diastolic BP > 100 mmHg); clinically significant valvular heart disease; or high risk uncontrollable arrhythmias.
- •Baseline LVEF < 50% (measured by echocardiography or MUGA).
- •Patients with dyspnea at rest due to complications of advanced malignancy or other disease, or who require supportive oxygen therapy.
- •Patients receiving chronic or high dose corticosteroid therapy. (Inhaled steroids and short courses of oral steroids for anti-emesis or as an appetite stimulant are allowed).
- •Clinically significant hearing abnormality.
- •Known dihydropyrimidine dehydrogenase (DPD) deficiency.
- •History or clinical evidence of brain metastases.
- •Serious uncontrolled systemic intercurrent illness, e.g. infections or poorly controlled diabetes.
- •Positive serum pregnancy test in women of childbearing potential.
- •Subjects with reproductive potential not willing to use an effective method of contraception.
- •Received any investigational drug treatment within 4 weeks of start of study treatment.
- •Radiotherapy within 4 weeks of start of study treatment (2 week interval allowed if palliative radiotherapy given to bone metastatic site peripherally and patient recovered from any acute toxicity).
- •Major surgery within 4 weeks of start of study treatment, without complete recovery.
- •History of HIV infection, Patients with known active infection with HBV, or HCV.
- •Known hypersensitivity to any of the study drugs.
研究组 & 干预措施
Herceptin+XELOX
Experimental
干预措施: Herceptin+XELOX (Drug)
结局指标
主要结局
Overall response rate
时间窗: 1 year
To evaluate the overall response rate for patients treated with trastuzumab combinated with capecitabine plus oxaliplatin.
次要结局
- Progression free survival(1 year)
- Overall survival(1 year)
- Time to progression(1 year)
- Duration of response(1 year)
研究者
Yoon-Koo Kang
Professor
Asan Medical Center
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)Breast CancerNCT04922008Fudan University356
进行中（未招募）
2 期
Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)Breast CancerNCT04383275Fudan University367
Unknown
2 期
Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal CancerMetastatic Colorectal CancerNCT03225937Fondazione del Piemonte per l'Oncologia54
招募中
2 期
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast CancerEarly-stage Breast CancerHormone Receptor Positive Breast CarcinomaStage II Breast CancerStage IIA Breast CancerStage IIB Breast CancerStage III Breast CancerInvasive Breast CancerNCT04553770Jonsson Comprehensive Cancer Center88
Unknown
2 期
Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast CancerHER-2 Positive Breast CancerNCT01428414Zhimin Shao100